“Peanut allergy is the most common persistent food allergy and has a huge impact on the lives of affected children and their families," she said. "Treatment options are needed.
"The benefit of this skin patch (epicutaneous) treatment is that it is safe and well tolerated. It is anticipated that it will play an important role in the treatment of peanut allergy in the future.
"Further studies are being carried out that will give us more information on the benefits of the patch. At this time the product is not licensed for use outside of a research setting.”
Fiona O'Malley, Head of Communications at CMRF Crumlin, said the best way to find gentler treatments, faster diagnoses and someday cures for childhood illnesses and allergies is by funding medical research programmes.
The children’s charity is currently funding 43 active research grants into cardiology, immunology, infection, allergies, cancer and neonatology. Members of the public who want to help support these research trials can go to www.cmrf.org/donate.